Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics
GET POWR RATINGS... FREE!
FENC POWR Grades
- Growth is the dimension where FENC ranks best; there it ranks ahead of 44.14% of US stocks.
- The strongest trend for FENC is in Momentum, which has been heading down over the past 31 weeks.
- FENC's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).
FENC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for FENC is 0.01 -- better than just 8.34% of US stocks.
- For FENC, its debt to operating expenses ratio is greater than that reported by only 0.51% of US equities we're observing.
- FENC's price/sales ratio is 1,012.58; that's higher than the P/S ratio of 99.03% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Fennec Pharmaceuticals Inc are SRRA, CAPR, VBIV, VTGN, and OTIC.
- Visit FENC's SEC page to see the company's official filings. To visit the company's web site, go to www.fennecpharma.com.
FENC Price Target
For more insight on analysts targets of FENC, see our FENC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.40 | Average Broker Recommendation | 1.4 (Strong Buy) |
FENC Stock Price Chart Interactive Chart >
FENC Price/Volume Stats
| Current price | $6.53 | 52-week high | $10.67 |
| Prev. close | $6.65 | 52-week low | $4.80 |
| Day low | $6.32 | Volume | 252,500 |
| Day high | $6.70 | Avg. volume | 108,941 |
| 50-day MA | $6.61 | Dividend yield | N/A |
| 200-day MA | $7.13 | Market Cap | 169.80M |
Fennec Pharmaceuticals Inc. (FENC) Company Bio
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.
Latest FENC News From Around the Web
Below are the latest news stories about Fennec Pharmaceuticals Inc that investors may wish to consider to help them evaluate FENC as an investment opportunity.
Here's Why We're Not Too Worried About Fennec Pharmaceuticals' (NASDAQ:FENC) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
Fennec Pharma resubmits PEDMARK application in U.S.Fennec Pharmaceuticals (FENC) has resubmitted its New Drug Application ((NDA)) to the FDA for PEDMARK (a unique formulation of sodium thiosulfate) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. The resubmission follows receipt of... |
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric PatientsFennec Pharmaceuticals Inc (NASDAQ: FENC ) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to the ear) induced by cisplatin chemotherapy … Full story available on Benzinga.com |
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~RESEARCH TRIANGLE PARK, N.C., May 28, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors. The resubmission for PEDMARK follows receipt of final minutes from a Type A meeting with the FDA. Importantly, the Complete Response Letter (CRL) received on August 10, 2020 referred t... |
Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~ ~ Company Has Approximately $27 Million in Cash and No Outstanding Debt ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the first quarter ended March 31, 2021 and provided a business update. “We remain on track to finalize and resubmit the New Drug Application for PEDMARKTM to the U.S. Food and Drug Administration in the second ... |
FENC Price Returns
| 1-mo | -3.55% |
| 3-mo | -8.29% |
| 6-mo | -11.99% |
| 1-year | -28.24% |
| 3-year | -40.37% |
| 5-year | N/A |
| YTD | -12.35% |
| 2020 | 14.79% |
| 2019 | 1.72% |
| 2018 | -36.33% |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...